Akums Drugs & Pharmaceuticals Ltd IPO
Open Demat Account
Akums Drugs & Pharmaceuticals Ltd IPO Details
Details
| Total Shares Offered | Offer to Public | Retail Max (Shares) | Pre Issue Promoters Holding | Exchange | Issue size |
|---|---|---|---|---|---|
| ₹ 273.45 L | ₹ 173.3 L | ₹ 27.12 L | ₹ 1,214.66 L | BSE | ₹ 1856.74 Cr |
| IPO Open Date | Close Date | Lot Size | Min Investment | Issue Type | Listing Date |
| 30 Jul, 24 | 01 Aug, 24 | 22 | ₹ 14,212 | Book Building | 06 Aug, 24 |
Akums Drugs & Pharmaceuticals Ltd IPO Dates
Details
| Sector | Type |
|---|---|
| Sector | Pharmaceuticals - Indian - Bulk Drugs & Formln |
| Sub Sector | NA |
| Issue Type | Book Building |
Subscription Status
*Values are in Lakhs
| Investor Type | Subscription Times | Shares Offered* | Shares Bid* |
|---|---|---|---|
| QIB | 36.04x | 20343188 | 733117770 |
| NII | 42.21x | 4068637 | 171750128 |
| Retail | 21.3x | 2712425 | 57770020 |
| Employee | 4.71x | 220913 | 1041216 |
| Total | 35.24x | 27345163 | 963679134 |
Subscription Status
Investor Type
QIB
NII
Retail
Employee
Total
*Values are in Lakhs
Akums Drugs & Pharmaceuticals Ltd Financial Status
Income Statement
Balance Sheet
| Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
|---|---|---|---|
| Revenue from operations | 3,654.82 | 3,671.89 | -169.10 |
| EBITDA | 210.32 | -279.45 | -143.00 |
| PAT | 125.43 | -381.78 | -145.43 |
| Total Assets | 551.03 | 562.95 | 416.80 |
| Share Capital | 28.61 | 14.31 | 1.30 |
| Total Borrowings | 234.52 | 176.07 | 130.94 |
| Operating Activities (Net Cash) | 155.43 | -354.02 | -119.33 |
| Investing Activities (Net Cash) | 122.91 | 140.87 | 148.20 |
| Financing Activities (Net Cash) | 234.52 | 176.07 | 130.94 |
| Net Cashflow | 8.85 | 25.74 | 1.00 |
Particulars (in Rs. Crores)
Revenue from operations
EBITDA
PAT
Total Assets
Share Capital
Total Borrowings
Operating Activities (Net Cash)
Investing Activities (Net Cash)
Financing Activities (Net Cash)
Net Cashflow
About Akums Drugs & Pharmaceuticals Ltd
The Company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi (RoC). The Company received a certificate of commencement of business issued by the RoC dated May 13, 2004.
The pharmaceutical industry in India is characterized by significant challenges, including, high capital expenditure required to establish and maintain sizeable manufacturing units, research and development expertise, trained manpower, consistent quality control, pricing pressure, disruptions within the supply chain, and the long-drawn regulatory and client approval and inspection processes, among others. An increase in chronic patient population, insurance penetration, trade generics, demand from tier II and III cities, and Government schemes focused on drug access are supporting growth in the Indian pharmaceutical market. Contract Development and Manufacturing Organizations assist pharmaceutical companies to employ an asset-light model and access global and specialized expertise while staying abreast with rapid innovation launches.
Bulkcorp International Limited is a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. The Company is also engaged in the sale of branded pharmaceutical formulations and manufacturing of active pharmaceutical ingredients. Some of its other services include formulation research and development, preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. Some of its manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation.
Peer Comparison:
- Divi's Laboratories Ltd
- Suven Pharmaceuticals Ltd
- Gland Pharma Ltd
- Torrent Pharmaceuticals Ltd
- Alkem Laboratories Ltd
- ERIS Lifesciences Ltd
- J B Chemicals & Pharmaceuticals Ltd
- Mankind Pharma Ltd
- Innova Captab Ltd
Akums Drugs & Pharmaceuticals Ltd IPO Key Points
Strengths
- Largest India-focused CDMO serving the Indian domestic pharmaceutical industry.
- Diverse client base with longstanding CDMO relationships.
- Large and rapidly growing R&D capabilities across its product portfolio.
- Strategic presence across the pharmaceutical value chain.
- Experienced and entrepreneurial management team with a proven track record and marquee healthcare focused PE investor.
Risk
- Its manufacturing units and research and development centres are concentrated in Haridwar, Uttarakhand and the company is exposed to risks originating from economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.
- Any slowdown or shutdown in its manufacturing and research and development operations could have an adverse effect on its business, results of operations, financial condition and cash flows.
- Any manufacturing or quality control concerns or its inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by its clients and distributors, which could have an adverse effect on its business, results of operations, financial condition and cash flows.
Strategy
- Leverage its leadership position to continue to increase its market share and consolidate its position in the CDMO market.
- Sustaining R&D for product development across therapies and dosage forms.
- Grow its domestic formulations business.
- Expanding its global presence through strategic initiatives.
- Scale its API business.
- Largest India-focused CDMO serving the Indian domestic pharmaceutical industry.
- Diverse client base with longstanding CDMO relationships.
- Large and rapidly growing R&D capabilities across its product portfolio.
- Strategic presence across the pharmaceutical value chain.
- Experienced and entrepreneurial management team with a proven track record and marquee healthcare focused PE investor.
How To Apply for Akums Drugs & Pharmaceuticals Ltd IPO Online?
Step 1:
Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.
Step 2:
From the list of open IPOs, select the IPO you want to invest.
Step 3:
Go through the IPO details like lot size, price band, about the company, etc.
Step 4:
Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.
Step 5:
Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.
